Ortomedic implants fall foul of Brazilian product registration
This article was originally published in Clinica
Executive Summary
Trading in four orthopaedic devices marketed in Brazil by Ortomedic Distribuidora de Implantes Ortopédicos has been suspended for not fulfilling the product registration and/or re-registration requirements, says national regulatory agency Anvisa. They are: Spacevision Acif, Sistema Espinhal Toracolombar Vers�til Uni-Thread, Sistema Universal de Ligação de Eixo Plus and Spacevision Plif, according to an alert notice posted on September 17. A formal notice issued to Ortomedic on September 16 gives the São Bernardo do Campo, São Paulo firm 30 days to provide the missing "economic information", as required under Resolution RDC 185, of October 2006.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.